An innovative gynecological HDR brachytherapy applicator system for treatment delivery and real-time verification by Romanyukha, Anna et al.
University of Wollongong 
Research Online 
Faculty of Engineering and Information 
Sciences - Papers: Part B 
Faculty of Engineering and Information 
Sciences 
2019 
An innovative gynecological HDR brachytherapy applicator 
system for treatment delivery and real-time verification 
Anna Romanyukha 
University of Wollongong, ar947@uowmail.edu.au 
Mauro Carrara 
Fondazione Irccs Istituto Nazionale Tumori 
Davide Mazzeo 
Universita degli Studi di Milano 
Chiara Tenconi 
Universita degli Studi di Milano 
Tebarak Al-Salmani 
University of Wollongong 
See next page for additional authors 
Follow this and additional works at: https://ro.uow.edu.au/eispapers1 
 Part of the Engineering Commons, and the Science and Technology Studies Commons 
Recommended Citation 
Romanyukha, Anna; Carrara, Mauro; Mazzeo, Davide; Tenconi, Chiara; Al-Salmani, Tebarak; Poder, Joel; 
Cutajar, Dean L.; Fuduli, Iolanda; Petasecca, Marco; Bucci, Joseph A.; Cerrotta, Annamaria; Pappalardi, 
Brigida; Piccolo, Federica; Pignoli, Emanuele; and Rosenfeld, Anatoly B., "An innovative gynecological HDR 
brachytherapy applicator system for treatment delivery and real-time verification" (2019). Faculty of 
Engineering and Information Sciences - Papers: Part B. 2818. 
https://ro.uow.edu.au/eispapers1/2818 
Research Online is the open access institutional repository for the University of Wollongong. For further information 
contact the UOW Library: research-pubs@uow.edu.au 
An innovative gynecological HDR brachytherapy applicator system for treatment 
delivery and real-time verification 
Abstract 
The multichannel vaginal cylinder (MVC) applicator employed for gynecological high dose rate (HDR) 
brachytherapy increases dose delivery complexity, and thus makes the treatment more prone to errors. A 
quality assurance (QA) procedure tracking the source throughout dose delivery can detect dwell position 
and time errors in the multiple channels of the applicator. 
A new MVC system with integrated real time in vivo treatment delivery QA has been developed based on 
diodes embedded on the outer surface of the MVC. It has been pre-calibrated and verified using a non-
clinical treatment plan with consecutive test positions and dwell times within each catheter, followed by 
the delivery of ten clinical plans of adjuvant vaginal cuff brachytherapy following hysterectomy for 
endometrial cancer. 
The non-clinical verification showed overall mean dwell position and time discrepancies between the 
nominal and measured treatment of −0.2 ± 0.5 mm and −0.1 ± 0.1 s (k = 1), respectively. The clinical plans 
showed mean positional discrepancies of 0.2 ± 0.4 and 0.0 ± 0.8 mm, for the central and peripheral 
catheters, respectively, and mean dwell time discrepancies of −0.1 ± 0.2 and −0.0 ± 0.1 s for central and 
peripheral catheters, respectively. 
The innovative prototype of the MVC system has shown the ability to track the source with sub-mm and 
sub-second accuracy, and demonstrated potential for its incorporation into the clinical routine. 
Disciplines 
Engineering | Science and Technology Studies 
Publication Details 
Romanyukha, A., Carrara, M., Mazzeo, D., Tenconi, C., Al-Salmani, T., Poder, J., Cutajar, D., Fuduli, I., 
Petasecca, M., Bucci, J., Cerrotta, A., Pappalardi, B., Piccolo, F., Pignoli, E. & Rosenfeld, A. (2019). An 
innovative gynecological HDR brachytherapy applicator system for treatment delivery and real-time 
verification. Physica Medica: an international journal devoted to the applications of physics to medicine 
and biology, 59 151-157. 
Authors 
Anna Romanyukha, Mauro Carrara, Davide Mazzeo, Chiara Tenconi, Tebarak Al-Salmani, Joel Poder, Dean 
L. Cutajar, Iolanda Fuduli, Marco Petasecca, Joseph A. Bucci, Annamaria Cerrotta, Brigida Pappalardi, 
Federica Piccolo, Emanuele Pignoli, and Anatoly B. Rosenfeld 
This journal article is available at Research Online: https://ro.uow.edu.au/eispapers1/2818 
-	1	-			
	
 
An innovative gynecological HDR brachytherapy applicator system for treatment 
delivery and real-time verification 
 
 
Anna Romanyukha1, Mauro Carrara2,*, Davide Mazzeo3, Chiara Tenconi4, Tebarak Al-Salmani1, 
Joel Poder5, Dean Cutajar1, Iolanda Fuduli1, Marco Petasecca1, Joseph Bucci5, Annamaria 
Cerrotta6, Brigida Pappalardi6, Federica Piccolo6, Emanuele Pignoli2, Anatoly Rosenfeld1 
 
 
1Centre for Medical Radiation Physics, University of Wollongong, Wollongong, NSW, Australia 
2Medical Physics Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy 
3Department of Physics, Università degli Studi di Milano, Milan, Italy 
4Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milan, Italy 
5St George Cancer Care Center, Kogarah, NSW, Australia 
6Radiation Oncology 2 Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy 
 
 
Keywords: HDR brachytherapy; multichannel vaginal applicator; source tracking; diodes; in 
vivo treatment QA 
 
*Corresponding author: 
Mauro Carrara 
Medical Physics Unit, Dept. of Diagnostic Imaging and Radiotherapy  
Fondazione IRCCS Istituto Nazionale dei Tumori 
Via Venezian, 1 
20133 Milano 
 
Phone: +39 02 2390 2123 
Fax: +39 02 2390 2124 
e-mail: mauro.carrara@istitutotumori.mi.it 
  
-	2	-			
	
 
Abstract 
The multichannel vaginal cylinder (MVC) applicator employed for gynecological high dose rate 
(HDR) brachytherapy increases dose delivery complexity, and thus makes the treatment more 
prone to errors. A quality assurance (QA) procedure tracking the source throughout dose delivery 
can detect dwell position and time errors in the multiple channels of the applicator. 
A new MVC system with integrated real time in vivo treatment delivery QA has been developed 
based on diodes embedded on the outer surface of the MVC. It has been pre-calibrated and 
verified using a non-clinical treatment plan with consecutive test positions and dwell times within 
each catheter, followed by the delivery of ten clinical plans of adjuvant vaginal cuff 
brachytherapy following hysterectomy for endometrial cancer. 
The non-clinical verification showed overall mean dwell position and time discrepancies between 
the nominal and measured treatment of –0.2 ± 0.5 mm and -0.1 ± 0.1 s (k=1), respectively. The 
clinical plans showed mean positional discrepancies of 0.2 ± 0.4 and 0.0 ± 0.8 mm, for the central 
and peripheral catheters, respectively, and mean dwell time discrepancies of -0.1 ± 0.2 and -0.0 ± 
0.1 s for central and peripheral catheters, respectively. 
The innovative prototype of the MVC system has shown the ability to track the source with sub-
mm and sub-second accuracy, and demonstrated potential for its incorporation into the clinical 
routine. 
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1. Introduction 
The multichannel vaginal cylinder (MVC) applicator has been widely adopted in gynecological 
high dose rate (HDR) brachytherapy (BT) treatments. It has shown reductions in doses received 
by organs-at-risk, as compared to the single channel vaginal cylinder (SVC) applicator, without 
compromising the dose to the target. In fact, as compared to SVC the MVC geometry provides 
more degrees of freedom (i.e., the source is also dwelling in peripheral channels) to optimize the 
dose distribution for each patient [1-5]. 
The presence of multiple channels increases treatment complexity, and thus makes HDR 
treatments more prone to error. Errors can arise as a result of transfer tube misconnections, 
afterloader malfunction, and mistakes in afterloader calibration, among others, and thus affect 
source stepping distances, dwell times, and dwell positions within the applicator. Moreover, 
treatment errors often remain unknown due to a lack of real-time or post-treatment dose delivery 
verification in the current treatment flow [6, 7]. 
Treatment verification is recommended in order to ensure optimal outcomes for the patient, and 
can be done by measuring or visualizing the HDR source during dose delivery either as a quality 
assurance (QA) procedure performed prior to treatment delivery, or for in vivo treatment QA. 
Methods have been investigated with systems such as ion chamber [8] and two-dimensional (2D) 
diode arrays [9], pixelated detectors [10], Gallium Nitride (GaN) probes [11], electronic portal  
imaging devices (EPIDs) [12], plastic scintillators [13,14], diamond detectors [15], fluorescent 
screen imaging [16], thermoluminescence dosimeters (TLDs) [17] and Alanine [18]. However, to 
the best of our knowledge, among the listed methods only GaN-based dosimeters have been used 
to perform in vivo QA of treatments delivered with MVCs. Alternative source tracking systems 
that allow sub-millimeter and sub-second dwell position and dwell time verification in real-time 
should therefore still be investigated.  
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The aim of this study was to produce and assess an innovative prototype of a MVC applicator 
with embedded and pre-calibrated diode detectors that can provide in vivo and real time QA of 
the delivered treatment by comparing it to the prescribed plan.  
 
2. Materials and Methods 
2.1 MVC prototype description 
The applicator prototype was designed and manufactured at the Centre for Medical Radiation 
Physics (CMRP) at the University of Wollongong. It is 30 mm in diameter and contains seven 
equally spaced peripheral channels and one central cavity to host the peripheral and central 
catheters of the commercially available Vaginal CT/MR Multi Channel Applicator (Elekta 
Brachytherapy, TH Veenendaal, NL), respectively. In particular, the peripheral catheters are 
disposable plastic catheters with a diameter of 2 mm and an external length of 293 mm (i.e., 
“catheter with collar 6F”) and the central catheter is the reusable Intravaginal CT/MR Tube. 
Epitaxial (epi) diode detectors were selected for HDR source tracking due to their high sensitivity 
and radiation hardness, and embedded on the applicator surface. The diodes are fabricated on p-
type epitaxial silicon with a sensitive volume of 1.5 x 1.5 x 0.5 mm3. They are connected to an in-
house developed reader based on the multichannel electrometer Application Specific Integrated 
Circuit (ASIC) that is able to accommodate up to 32 detectors for simultaneous readout. Even 
though the current integration of the diode is performed at an interval of 1 ms, the output signal 
was averaged to 50 measurements to increase the signal to noise ratio, resulting in a final readout 
frequency of 20 Hz. Accompanying readout software was also developed at the CMRP to display 
the instantaneous and integral responses of the connected detectors in real-time. The raw output 
signal of each detector is automatically stored for post-measurement analysis. A more detailed 
description and characterization of the epi-diodes and data acquisition (DAQ) readout system is 
provided elsewhere [9, 19].  
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The applicator prototype was assembled by placing three diodes into dedicated grooves with an 
angular interval of about 120 degrees around the surface of the MVC applicator at distances of 
35, 37, and 39 mm from the applicator tip, respectively, ensuring a detection coverage of the 
proximal 6-7 cm of the vagina. Since in adjuvant vaginal cuff BT following hysterectomy, as a 
routine, it is recommended that the proximal 3-5 cm of the vagina be treated [20], the selected 
diode arrangement would be appropriate to cover the clinically significant region. A phantom of 
160 x 220 x 160 mm3 was fabricated using polymethylmethacrylate (PMMA) to surround the 
applicator without any air gaps and ensure adequate scattering conditions. A picture of the 
experimental setup used to perform all measurements of this study is shown in figure 1. The 
MVC system is positioned inside the PMMA phantom with transfer tube connections in all 
existing channels. The three diodes are connected to the DAQ system for readout, and read out in 
real time throughout the irradiation outside the BT bunker.  
 
2.2 Afterloader description 
Measurements were performed using the Flexitron afterloading unit (Elekta Brachytherapy, TH 
Veenendaal, NL) at the BT facility of the Fondazione IRCSS Istituto Nazionale dei Tumori (INT) 
in Milan, Italy. The afterloader contains an Ir-192 source with a 3.5 mm active length 
(Flexisource, Elekta) that is attached to a steel wire [21] and can be delivered using a total of 40 
available treatment channels. The Air Kerma Strength SK of the source ranges between about 45 
(when it is installed in the afterloader) and 20 mGy m2 h-1 (when it is removed and replaced). The 
unit allows a minimal step size and dwell time of 1 mm and 0.1 seconds, respectively. The 
positional accuracy of the system is ± 0.5 mm [22].  
 
2.3 MVC system calibration  
The first part of the study concerns the calibration of the MVC system - that is to assign to the 
measured response of the diodes a source dwell time and position (with respect to a specific 
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reference point) within the applicator catheters of the MVC system. The dwell position was 
defined as the center of the active length of the source. The origin of the reference system was set 
on the upper surface of the MVC applicator and the absolute location of the first dwell position in 
each of the seven peripheral applicator channels was determined using GafChromic film 
measurements. The film was wrapped around the applicator surface, aligning the edge with the tip 
of the applicator, and the source was sent to the first dwell position (i.e., the most distal with 
respect to the afterloader) for a dwell time of 3 seconds. Position locations exposed on the 
GafChromic film were evaluated using a Matlab (The Mathworks, Natick, MA, USA) script to 
determine the center of each Ir-192 exposure and its location with respect to the edge of the film. 
Measurements were repeated three times, and the obtained average locations of the first dwell 
position, given as the distance (mm) from the applicator surface, ± 0.1mm (k=1), were 7.1 mm, 
6.9 mm, 6.8 mm, 7.1 mm, 6.9 mm, 6.5 mm and 6.5 mm, for the peripheral catheters 1 to 7, 
respectively. The first dwell position in the central catheter was set as 5.5 mm and was taken from 
the Elekta user manual. 
 
2.3.1 MVC calibration for source dwell position detection 
To calibrate the MVC system in terms of source position detection, the relationship between 
diode response and source position was investigated. The source was sent to dwell positions of 
1100-1288 mm in the peripheral channels and 1100-1300 mm in the central channel, respectively, 
at a step size of 1 mm and a dwell time of 1 second in each position. 1288 mm and 1300 mm are 
the first dwell positions (i.e., maximal distal positions) that can be set for the peripheral and 
central catheters, respectively.  
The output was normalized by SK at the time of measurement and averaged over all the readout 
values corresponding to a near-constant diode response, and thus indicating a single programmed 
dwell position (i.e., readouts corresponding to the source transiting from one dwell position to the 
other when the response of the diode was monotonically variable were eliminated). The obtained 
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mean responses R!"#!$ were plotted as a function of the source distance dcath from the applicator 
tip, and those belonging to the two diodes with the higher signals were fitted with multi-term 
Gaussian functions according to equation 1: 
R!"#!$(𝑑!"#!)  =  a! ∙ e
(!!"#!!!!!!
)! +  a! ∙ e
(!!"#!!!!!!
)! +⋯   Eq. 1 
where an, bn and cn are the fitting parameters of the n-th term of the equation.  
Thus, once the multi-term Gaussian functions are defined for the source dwelling in every 
available catheter they can be used for finding the source dwelling position dcath in the given 
catheter at any time. The multi-term Gaussian-interpolated diode response function (normalized 
by the source SK) provides two possible solutions for the source dwell position. The ambiguity of 
source position determination is avoided by taking into account the response of a second diode 
located in a slightly different depth relative to the tip of the catheter in comparison to the diode 
with highest response, as shown in figure 2. 
A schematic of the applicator with the three diodes positioned on its surface is shown in figure 2. 
An example of the diode response with the source dwelling in the central catheter is plotted as a 
function of the source distance from the applicator tip. In this example, the diodes 1 and 3 were 
selected as reference diodes for dwell position and time reconstruction. 
 
2.3.2 MVC calibration for source dwell time detection 
Source dwell time is determined from the plateaus in the diode signal i.e., the constancy of diode 
response with respect to the time. Dwell time is calculated as the ratio of the number of 
measurements in each plateau and the frequency of readout, set at 20 Hz throughout this study. 
An example of a plot with clearly distinguishable consecutive dwelling position plateaus is given 
in figure 3 for dwells of five second duration. 
 
2.4 MVC system verification  
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The system’s ability to reconstruct Ir-192 dwell positions and dwell times using the established 
methodology was first verified using a test plan with multiple consecutive dwell positions in 
every one of the eight applicator catheters. Chosen dwell positions with a step-size of 10 mm 
covered a range of 60 mm and 70 mm (i.e., from 5.5 to 75.5 mm from the applicator tip) in the 
peripheral and central channels, respectively, and were delivered for a dwell time of 5 seconds in 
each position. The absolute differences Δp and Δt between nominal and measured dwell positions 
and times, respectively, were then computed for every source position according to Δp = pmeas - 
pnom and Δt = tmeas - tnom. 
Following the first verification study, a total of ten BT treatments previously delivered at the 
Fondazione IRCCS Istituto Nazionale dei Tumori to cervical cancer patients employing the 30-
mm MVC, were randomly selected from the database and delivered in-phantom. Overall, 181 and 
106 dwell positions for the source dwelling in the central and in the lateral catheters, respectively, 
were planned. Discrepancies between reconstructed and nominal dwell positions and times were 
evaluated as described above. 
 
 
3. Results 
 
The quality of fitting parameters derived for the diode response functions used for dwell position 
reconstruction in each catheter can be seen in table 1. The two diodes with the highest signal, the 
number of Gaussian terms used for the interpolation curve, and their corresponding R2 values are 
provided. 
Following calibration of the MVC system, dwell position-time plots as those shown in figure 4 
could be obtained for treatment delivery verification. An example of the source dwelling in the 
central catheter during the delivery of the non-clinical plan (a), and of a complete clinical 
treatment plan (i.e., central and the six peripheral channels C2 to C7) (b), are provided. 
The distributions of all resulting dwell time and position discrepancies for the non-clinical plan 
(i.e., step-size of 10 mm, dwell time 5 s in all available catheters) are given in figure 5, with the 
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mean discrepancies for each single catheter reported in table 2. Overall mean dwell position and 
time discrepancies were determined as –0.2 ± 0.5 mm and -0.1 ± 0.1 s (k=1), respectively. 50% 
and 95% of absolute positional discrepancies were within 0.4 mm and 1.3 mm, respectively, 
whereas 50% and 95% of absolute time discrepancies were within 0.1 s and 0.4 s, respectively.  
Discrepancy distributions between nominal and reconstructed dwell positions and times for all 10 
delivered clinical treatment plans are plotted in figure 5. The mean dwell position discrepancies 
are 0.2 ± 0.4 mm and 0.0 ± 0.8 mm (k=1) for the central and lateral catheters, respectively. The 
mean dwell time discrepancies are -0.1 ± 0.2 s and -0.0 ± 0.1 s (k=1) for the central and lateral 
catheters, respectively. 
In general, 50% and 95% of absolute positional discrepancies |Δp| were < 0.3 mm and < 0.8 mm 
for the source dwelling in the central catheter, respectively, and < 0.5 mm and < 1.5 mm for the 
source dwelling in the peripheral catheters, respectively. Overall, 96.2 and 77.9% of absolute 
positional discrepancies were < 1 mm for the central and peripheral channels, respectively. 
50% and 95% of absolute dwell time discrepancies |Δt| were < 0.05 s and < 0.40 s, respectively, 
for the source dwelling in the central catheter, and < 0.05 s and < 0.20 s, respectively, for the 
source dwelling in the peripheral catheters.  
Figure 6 provides a graphical visualization of the correspondence between planned (i.e., nominal) 
and measured dwell positions and times for the central and lateral catheters of the 10 delivered 
clinical treatment plans. Higher discrepancies between planned and real dwell positions and times 
are shown by the higher gaps between the red (nominal) and blue (measured) data points. 
 
4. Discussion 
In this study, an innovative prototype of a MVC applicator with embedded diode detectors was 
produced. Preliminary measurements on a non-clinical and on 10 different clinical treatment 
plans have demonstrated the MVC system’s ability to monitor the HDR source throughout the 
entire dose delivery phase, providing in vivo and real time QA of the delivered treatment by 
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comparing it to the prescribed plan. The system is in principle able to detect errors in dwell 
position and dwell times, including spontaneous afterloader malfunction, incorrect applicator and 
indexer lengths, mistakes in transfer tube connections, source calibration, and administration of 
the incorrect treatment plan. 
A great advantage is that the MVC system can be pre-calibrated via a relatively easy method, and 
source positions and times can be obtained in real time without any assumptions or particular 
dose distribution calculations within the applicator/patient. In fact, source positions are 
constrained along the central and peripheral catheters, and the diodes have fixed positions with 
respect to the catheters. Thus, for each possible source position in one of the eight treatment 
channels, a unique solution exists from the combination of the two dosimeters with the highest 
responses. This solution can be determined experimentally prior to the use of the applicator and is 
valid without further recalibration in the case of stable diode response. Therefore, only a QA of 
the diode stability with time is required. Moreover, specific corrections for the possible energy 
and angular dependences of the diodes were not necessary, because the overall diode response 
was taken as reference and intrinsically modeled with the multi-term Gaussian functions. 
This is different to systems that are not built-in with the applicator, such as 2D arrays [8,9] or 
EPIDs [12], where more complex assumptions, pre-calibrations and calculations have to be 
performed to accurately reconstruct source positions inside the patient. For a correct calibration of 
the MVC system, it is however very important that it is calibrated in the same conditions that are 
present during treatment. Therefore, in order to ensure full-scattering conditions, a phantom was 
fabricated to surround the applicator during calibration, without leaving any air gaps at the 
applicator-phantom interface. 
Another advantage of the proposed system over previously developed methods is that the diodes 
used for Ir-192 tracking are incorporated directly over the dose delivery instrument, i.e., MVC 
applicator, eliminating the introduction of any additional steps into the existing treatment 
procedure for the radiation oncologist or the radiation therapy technologist. Prior to patient 
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irradiation the diode detectors must simply be connected to the readout system. For full system 
integration into the QA workflow, the readout system should ideally be connected with the 
afterloader treatment console for a direct comparison between nominal (i.e., planned on the 
console) and delivered (detected with the MVC system and calculated directly on the console) 
dwell position and times. 
The proposed pre-calibrated MVC system is the first prototype of the multichannel vaginal 
cylindrical applicator with embedded diode detectors that can provide dwell positions and times 
with generally sub-mm and sub-second accuracy in real time. To the best of our knowledge, it is 
the first time ever that such a system is presented in literature. In fact, Wang et al [23] and Guiral 
et al [24] also equipped a commercial MVC applicator with four GaN-based dosimeters. They 
proposed a method for accurate in vivo determination of source dwell times and positions as a 
QA of the delivered treatment plan. Despite the very promising error detectability shown and 
evaluated in-phantom by means of testing intentionally introduced error protocols, a drawback of 
the proposed system remains in the reduction of peripheral channels available for treatment. The 
GaN-based dosimeters were hosted in four of the available treatment channels, thus significantly 
limiting the dose distribution optimization potential of the MVC. Moreover, in Guiral et al, the 
results mainly concern the use of the central catheter and only a simple test was performed on a 
three channel instrumented applicator. 
If comparing the results limited to the central catheter, mean dwell position and time 
discrepancies are comparable. In particular, the discrepancies were -0.11 ± 0.7 mm and 0.2 ± 0.4 
mm (k=1) for dwell positions in Guiral et al and in our study, respectively, and 0.05 ± 0.09 s and 
-0.1 ± 0.2 s (k=1) for dwell  times, respectively. In our study, it was additionally shown that 
comparable accuracies can also be obtained for lateral catheters on 10 clinical treatments, with 
resulting dwell position and time discrepancies of 0.0 ± 0.8 mm and -0.0 ± 0.1 s (k=1), 
respectively.  
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This study clearly shows feasibility of the method and a potential for future use of the MVC 
system in the clinical routine. In principle, the diodes could be integrated to commercially 
available MVC applicators of any diameter, establishing the MVC system with applicators that 
are already clinically approved and familiar to operators. If these commercially available MVC 
systems will be designed with dedicated grooves that accommodate individual diodes and exactly 
fit the dimensions of the detectors, it will likely be possible that diodes could be removed and put 
back after each sterilization cycle without the need of a new calibration. On the contrary, 
recalibration will be necessary any time the diodes need to be replaced with new ones. Studies are 
still ongoing to define the most convenient adjustment to properly integrate the diodes with 
commercial applicators of different diameters  
A range of source detection within the applicator of the proximal 60-70 mm of the vagina is 
enough for the majority of clinical applications of adjuvant vaginal cuff BT after hysterectomy, 
since the proximal 3-5 cm of the vagina are usually treated [20]. The current detection range 
limitation is determined by a combination of diode sensitivity and their location over the 
applicator. An increased number of diodes and their optimal distribution over the applicator could 
in principle allow an extension of this range. Time and spatial resolutions are also in principle 
good and would already allow the detection of significant delivery errors. A thorough evaluation 
of the system’s ability to detect specific treatment errors will be conducted in the future. 
Nevertheless, it must be noted that some improvements could still be accomplished to realize an 
advanced version of the MVC system. In particular, since the diodes are particularly small and 
since the reader is able to accommodate up to 32 detectors for simultaneous readout, additional 
diodes could be added over the MVC surface. There could in principle be one diode at every 
inter-channel space and some of them could also be placed closer to the applicator tip or to the 
applicator end. In this case more than two diode responses could be used to mathematically 
calculate the source position. Such an advanced diode assembly could possibly further improve 
source detection accuracy, as for instance: i) in the tails of the current calibration curves, where 
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diode signal is lower (e.g. close to the tip of the applicator); ii) in the peak of the current 
calibration curves, where the source is dwelling directly above the sensitive volume of the diode 
and it is not possible to distinguish two consecutive dwell positions because these provide a 
similar response.  
Even if, in the latter case, the second diode, located a few mm away, is able to accurately identify 
the correct position between the two, an exception occurred in our study for source positions 35.5 
and 38.5 mm in catheter 2, where both of the diodes were not able to distinguish the two 
consecutive dwell positions, reconstructing both as 37.1 mm. By eliminating the current physical 
restraint of the system, i.e., the presence of seven peripheral catheters and only three diodes, 
resulting in catheter 2 having two diodes of a similar response, spatial uncertainties in close 
proximity to the diode’s sensitive volume could possibly be decreased. 
An intrinsic limitation of the developed method is that the source tracking system is incorporated 
to the MVC applicator, but no conclusions can be drawn about the anatomical delivery of the 
delivered dose distribution. The use of the system will therefore provide a valuable validation that 
the delivered treatment is in accordance with the planned one, but no conclusions can be drawn 
about the delivered dose distribution. In vivo dose measurements in the urethra or rectum 
[5,6,11,13,17,18,25] will additionally be needed to provide a comprehensive evaluation of the 
treatment. Further in vivo measurements are required to validate a possible combination of the 
dosimetry and source tracking methods. 
 
 
5. Conclusion 
The innovative prototype of a pre-calibrated MVC applicator with embedded diodes has shown 
the ability to track the HDR Ir-192 source during vaginal BT treatments with generally sub-mm 
and sub-second accuracy. The system is able to provide online verification of source dwell 
positions and times in real time for treatment verification, and there is potential for its future 
-	14	-			
	
application in the clinical routine. Thorough studies to analyze the MVC system’s ability to detect 
specific treatment errors and to investigate the possible combination of the MVC system with in 
vivo dosimetry methods will be conducted in the future. 
 
Acknowledgements 
We thank the Australian Research Council for scholarship support of A.A.R. through Laureate 
Fellowship grant FL130100116. This work was partially supported by the Italian Ministry of 
Health (5 x 1000 Funds – year 2014). 
 
References 
[1] Bahadur AY, Constantinescu C, Hassouna AH, Eltaher MM, Ghassal NM, NesreenAA. 
Single versus multichannel applicator in high-dose-rate vaginal brachytherapyoptimized by 
inverse treatment planning. J Contemp Brachytherapy. 2015;6:362–70. 
[2] Carrara M, Romanyukha A, Tenconi C, Mazzeo D, Cerrotta A, Borroni M, et al. Clinical 
application of MOSkin dosimeters to rectal wall in vivo dosimetry in gy-necological HDR 
brachytherapy. Phys Med. 2017; 41:5-12. 
[3] Carrara M, Cusumano D, Giandini T, Tenconi C, Mazzarella E, Grisotto S et al. Comparison 
of different treatment planning optimization methods for vaginal HDR brachytherapy with 
multichannel applicators: A reduction of the high doses to the vaginal mucosa is possible.  
Phys Med. 2017; 44:58-65. 
[4] Demanes DJ, Rege S, Rodriguez RR, Schutz KL, Altieri GA, Wong T. The use and 
advantages of a multi-channel vaginal cylinder in high-dose-rate brachytherapy. Int J Radiat 
Oncol Biol Phys. 1999;44:211–9. 
[5] Tanderup K, Lindegaard JC. Multi-channel intracavitary vaginal brachytherapy using three-
dimensional optimization of source geometry. Radiother Oncol. 2004;70:81–5. 
-	15	-			
	
[6] Kertzscher G, Rosenfeld A, Beddar S, Tanderup K, Cygler JE. In vivo dosimetry: trends and 
prospects for brachytherapy. Br J Radiol. 2014;87(1041):20140206. 
[7] Tanderup K, Beddar S, Andersen CE, Kertzscher G, Cygler JE. In vivo dosimetry in 
brachytherapy.  Med Phys. 2013; 40(7). 
[8] Manikandan A, Biplab S, David PA, Holla R, Vivek TR, Sujatha N. Relative dosimetrical 
verification in high dose rate brachytherapy using two-dimensional detector array IMatriXX. 
J Med Phys. 2011;36(3):171-5. 
[9] Espinoza A, Petasecca M, Fuduli I, Howie A, Bucci J, Corde S, et al. The evaluation of a 2D 
diode array in "magic phantom" for use in high dose rate brachytherapy pretreatment quality 
assurance. Med Phys. 2015;42(2):663-73. 
[10] Safavi-Naeini M, Han Z, Alnaghy S, Cutajar D, Petasecca M, Lerch ML, et al. BrachyView, 
a novel in-body imaging system for HDR prostate brachytherapy: Experimental evaluation. 
Med Phys. 2015;42(12):7098-107. 
[11] Cartwright LE, Suchowerska N, Yin Y, Lambert J, Haque M, McKenzie DR. Dose mapping 
of the rectal wall during brachytherapy with an array of scintillation dosimeters. Med Phys. 
2010;37(5):2247-55. 
[12] Smith RL, Haworth A, Panettieri V, Millar JL, Franich RD. 3D catheter reconstruction in 
HDR prostate brachytherapy for pre-treatment verification using a flat panel detector. Phys 
Med. 2017; 39:121-131. 
[13] Therriault-Proulx F, Briere TM, Mourtada F, Aubin S, Beddar S, Beaulieu L. A phantom 
study of an in vivo dosimetry system using plastic scintillation detectors for real-time 
verification of 192Ir HDR brachytherapy. Med Phys. 2011;38(5):2542-51. 
[14] Johansen JG, Rylander S, Buus S, Bentzen L, Hokland SB, Søndergaard CS et al . Time-
resolved in vivo dosimetry for source tracking in brachytherapy. Brachytherapy. 
2018;17:122-132 
-	16	-			
	
[15] Nakano T, Suchowerska N, McKenzie D, Bilek M. Real-time verification of HDR 
brachytherapy source location: implementation of detector redundancy. Phys Med Biol. 
2005;50(2):319. 
[16] Lightstone AW. Fluorescent screen for high-dose-rate (HDR) brachytherapy quality 
assurance. Med Dosim. 2005;30(3):143-4. 
[17] Anton M, Wagner D, Selbach HJ, Hackel T, Hermann RM, Hess CF et al. In vivo dosimetry 
in the urethra using alanine/ESR during (192)Ir HDR brachytherapy of prostate cancer-a 
phantom study. Phys Med Biol. 2009; 54: 2915-31  
 [18] Jaselskė E, Adlienė D, Rudžianskas V, Urbonavičius BG, Inčiūra A. In vivo dose 
verification method in catheter based high dose rate brachytherapy. Phys Med. 2017; 44:1-10.  
 [19] Aldosari AH, Petasecca M, Espinoza A, Newall M, Fuduli I, Porumb C, et al. A two 
dimensional silicon detectors array for quality assurance in stereotactic radiotherapy: 
MagicPlate-512. Med Phys. 2014;41(9):091707. 
[20] Small W, Beriwal S, Demanes DJ, Dusenbery KE, Eifel P, Erickson B, Jones E, Rownd JJ, 
De Los Santos JF, Viswanathan AN, Gaffney D; American Brachytherapy Society. American 
Brachytherapy Society consensus guidelines for adjuvant vaginal cuff brachytherapy after 
hysterectomy. Brachytherapy. 2012;11:58-67. 
[21] Perez-Calatayud J, Ballester F, Das RK, DeWerd LA, Ibbott GS, Meigooni AS, et al. Dose 
calculation for photon-emitting brachytherapy sources with average energy higher than 50 
keV: report of the AAPM and ESTRO. Med Phys. 2012;39(5):2904-29. 
[22] Van Der Laarse R, Niatsetski Y. Flexitron and MicroSelectron-HDR. PDR Afterloaders’ 
Transit Time and Dose (Elekta AB, Stockholm, Sweden, 2014). 2014. 
[23] Wang R, Ribouton J, Pittet P, Guiral P, Jalade P, Lu G-N. Implementation of GaN based 
real-time source position monitoring in HDR brachytherapy. Rad Meas. 2014;71:293-6. 
-	17	-			
	
[24] Guiral P, Ribouton J, Jalade P, Wang R, Galvan JM, Lu GN, et al. Design and testing of a 
phantom and instrumented gynecological applicator based on GaN dosimeter for use in high 
dose rate brachytherapy quality assurance. Med Phys. 2016;43(9):5240-51. 
[25] Gambarini G, Carrara M, Tenconi C, Mantaut N, Borroni M, Cutajar D et al. Online in vivo 
dosimetry in high dose rate prostate brachytherapy with MOSkin detectors: in phantom 
feasibility study. Appl Radiat Isot. 2014; 83:222-226  
-	18	-			
	
Figure captions 
Figure 1: (a) Cylindrical multichannel applicator with the peripheral catheters and three diodes 
positioned around its surface (the central catheter is not shown in the image); (b) Two cylindrical 
components of the MVC, with the possibility of using the intrauterine tube in the innermost piece 
of the applicator, and the custom-made PMMA phantom to surround the applicator; (c) 
experimental setup used for the study. 
 
Figure 2: Multi-term Gaussian functions in the central catheter where the cross-sectional 
horizontal view (a) of the applicator shows the Ir-192 source (red sphere) in the central channel, 
and the three color-coded diodes positioned on the applicator surface. Corresponding diode 
response curves are plotted as a function of the source distance from the applicator tip (b), and in 
this case the diodes with the highest response i.e., diodes 1 and 3 are used for position and dwell 
time reconstruction. The source in the dwell position is shown in the longitudinal view (c) with 
diodes 1 and 3 fixed around the applicator perimeter. 
 
Figure 3: Example of normalized diode response as seen during treatment time. Points between 
the plateaus are due to the transit of the source from one dwell position to the next one.   
 
Figure 4: Example of treatment delivery verification for a) catheter 1 of the test plan and for b) a 
complete clinical treatment plan (i.e., central and the six peripheral channels C2 to C7). The 
reconstructed and nominal dwell positions, shown in blue and red, respectively, are viewed as a 
function of treatment time. Plot b shows that the treatment starts in the furthest position from the 
applicator tip of the central catheter, delivering a total of 16 dwell positions of various dwell 
times. At 222.3 seconds the central channel delivery is completed (marked by the red arrow). The 
source then proceeds to two dwell positions 5 mm apart in peripheral channel 2 for 34.1 and 11.8 
s in duration, respectively, and one dwell position in channel 3. The source then dwells in two 
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positions in channel 4, 1 mm apart and lasting 33.7 s and 11.3 s, respectively, and then to one 
dwell position in consecutive channels 5, 6, and 7 for dwell times of 33.0 s, 21.7 s, and 33.3 s, 
respectively. 
 
Figure 5: Discrepancy distributions between nominal and reconstructed dwell positions (a) and 
times (c) for the non-clinical treatment, respectively, and for the 10 delivered clinical treatment 
plans (i.e., (b) and (d), respectively). For the clinical treatment, distinct distributions for the 
central and the peripheral catheters are shown. Histograms are fitted with Gaussian distributions, 
which are also plotted with continuous lines.  
 
Figure 6: Correspondence between the planned (red squares) and measured (blue dots) dwell 
positions (a) and times (c) for the central catheter, respectively, and between planned and 
measured dwell positions (b) and times (d) for the lateral catheters, respectively, in the 10 
delivered clinical patient plans. 
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Tables 
 
Table 1. Calibration curve parameters for each catheter. 
Catheter Diodes No. of Gaussian terms R
2 values 
HIGH LOW HIGH LOW HIGH LOW 
C1 D2 D3 4 3 1 >0.99 
C2 D2 D3 4 3 1 1 
C3 D3 D2 4 2 1 >0.99 
C4 D3 D1 4 2 1 >0.99 
C5 D1 D3 4 2 >0.99 >0.99 
C6 D1 D2 3 2 >0.99 >0.99 
C7 D2 D1 4 2 1 >0.99 
Central D1 D3 3 3 1 1 
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Table 2: Results of the non-clinical dwell position and dwell time verification study with mean 
absolute differences Δp and Δt between the nominal and measured dwell positions and times for 
each catheter within the MVC, respectively. 
Catheter Discrepancies 
CATHETER Δp (mm) Δt (s) 
C1 -0.2 ± 0.3 -0.2± 0.1 
C2 0.0± 0.4 -0.2± 0.1 
C3 -0.1± 0.4 -0.2± 0.1 
C4 -0.5± 0.6 -0.1± 0.2 
C5 -0.3± 0.5 -0.1± 0.0 
C6 -0.1± 0.5 -0.2± 0.2 
C7 -0.6± 0.5 -0.1± 0.1 
Central -0.1 ± 0.3 -0.1± 0.0 
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